Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials

Table 3 Risk analysis for non-CR, non-CC, and non-TC during the overall study period

	Univariable analysis			Multivariable analysis
	OR	95% CI	P value	OR	95% CI	P value
A: non-CR
Sex (female vs male)	4.59	1.26–16.78	0.021	2.50	0.54–11.63	0.241
Age (< 60 years vs > =60 years)	4.24	1.49–12.09	0.007	2.40	0.69–8.37	0.169
NK₁RA inclusive regimen (yes vs no)	2.89	0.79–10.58	0.110	1.43	0.33–6.14	0.628
CBDCA dose (6 vs 4–5)	2.44	0.81–7.34	0.113
Habitual alcohol consumption (yes vs no)	0.35	0.09–1.27	0.110
Motion sickness (yes vs no)	1.34	0.48–3.72	0.571
Morning sickness (yes vs no)	2.16	0.65–7.15	0.206
B: non-CC
Sex (female vs male)	3.69	1.16–11.76	0.027	1.78	0.43–7.37	0.430
Age (< 60 years vs > =60 years)	4.17	1.53–11.34	0.005	2.54	0.75–8.55	0.134
NK₁RA inclusive regimen (yes vs no)	3.39	0.94–12.25	0.063	1.89	0.46–7.78	0.378
CBDCA dose (6 vs 4–5)	2.20	0.79–6.18	0.133
Habitual alcohol consumption (yes vs no)	0.30	0.08–1.07	0.063
Motion sickness (yes vs no)	1.07	0.40–2.85	0.894
Morning sickness (yes vs no)	1.48	0.49–4.46	0.483
C: non-TC
Sex (female vs male)	3.77	1.62–8.76	0.002	1.69	0.60–4.76	0.323
Age (< 60 years vs > =60 years)	5.06	2.26–11.33	< 0.001	3.08	1.17–8.12	0.023
NK₁RA inclusive regimen (yes vs no)	3.23	1.30–8.01	0.012	1.47	0.49–4.46	0.492
ECOG PS (0–1 vs 2)	2.73	0.32–22.93	0.356
CBDCA dose (6 vs 4–5)	2.54	1.15–5.57	0.021	1.46	0.57–3.72	0.431
Habitual alcohol consumption (yes vs no)	0.66	0.29–1.47	0.310
Motion sickness (yes vs no)	0.69	0.32–1.49	0.340
Morning sickness (yes vs no)	1.62	0.69–3.77	0.264

OR odds ratio; CI confidence interval; CR complete response; CC complete control; TC total control; CBDCA carboplatin; ECOG PS Eastern Cooperative Oncology Group performance status.

ISSN: 1471-2407